Clinical trial NCT06328608: A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
Official title: Multi-centre, Open-label Trial to Assess the saFety, Pharmacodynamics, Efficacy and Pharmacokinetics of pegunigaLsidase Alfa in Patients From 2 Years to Less Than 18 Years of Age With Confirmed FabrY Disease
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
PHASE3
Conditions: Fabry Disease
Lead sponsor: Chiesi Farmaceutici S.p.A.
Sponsor class: INDUSTRY
Collaborators: name: ICON plc
First posted: 2024-03-25
Enrollment: 22
Sex: ALL
Minimum age (years): 2
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease.

Detailed description: This study aims to learn how safe pegunigalsidase alfa (PRX-102 for short) is and how it works at treating Fabry disease in children and adolescents.

PRX-102 is an enzyme replacement therapy (ERT), meaning it acts like a natural enzyme. PRX-102 is given through a needle placed in a vein (intravenous infusion) every two weeks.

The main questions this study aims to answer are:

* Which is the safest and most effective dose to be given to children and adolescents.
* Which effects PRX-102 has on signs and symptoms of Fabry disease (e.g. renal and cardiac function, pain, gastrointestinal symptoms)

  20 to 22 boys and girls with Fabry disease between the ages of 2 and 17 will be part of this study. There will be three age cohorts, with children aged 2 to 7 years included (enrolled) in Cohort A, children aged 8 to 12 years in Cohort B, and adolescents aged 13 to less than 18 years in Cohort C.

The study is divided into three parts, or "stages":

* A dose-finding stage (Stage I). In this stage, researchers will determine the dose for children.
* A confirmatory stage (Stage II). In this part, researchers will learn about the safety and efficacy of PRX-102.
* and an optional extension stage (Stage III) will continue until the study drug becomes commercially available or the Sponsor chooses to end this study.

PRX-102 will be given at the study visits, which will occur at least every two weeks. Tests for verifying the study drug's safety and efficacy and determining the dose will also be conducted at different time points throughout the study (not all tests will be done at all visits). These tests may include a review of any health problems and medications the participants have had or taken since the last visit; a physical examination; ECG; ultrasound of the heart; questionnaires that evaluate the nature and severity of Fabry disease symptoms, quality of life and pain; a collection of blood and urine samples for standard safety tests, to analyse the severity of Fabry disease and to see how the drug is behaving and how long it remains active in the body (this involves taking multiple blood samples over several days with the first sample taken just before the start of the PRX-102 infusion and the last one taken just before the start of the next PRX-102 at the next visit).

Eligibility criteria: Inclusion Criteria:

* Participants with the provision of informed consent from their legal guardians
* Boys and girls aged 2 to 7 years (Cohort A), 8 to 12 years (Cohort B), or 13 to \<18 years (Cohort C).
* Confirmed diagnosis of Fabry disease
* Presence of at least one of the following characteristic features of Fabry disease: neuropathic pain, cornea verticillata, and/or clustered angiokeratoma.
* History of Fabry pain: Fabry crises OR chronic pain.
* Clinical condition that, in the investigator's opinion, requires ERT treatment.

Exclusion Criteria:

All Subjects:

* Estimated glomerular filtration rate (eGFR) at screening \< 80 mL/min/1.73 m2.
* History of type I hypersensitivity reactions (anaphylactic or anaphylactoid life-threatening reaction) to other ERT treatment for Fabry disease or any component of the study drug.
* Initiation of treatment with an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) or a dose change in ongoing treatment in the four weeks before screening.
* Urine protein to creatinine ratio (UPCR) \> 0.5 g/g (0.5 mg/mg or 500 mg/g) if not treated with an ACE inhibitor or ARB.
* Currently taking another investigational drug for any condition.
* History of acute kidney injury in the 12 months before screening, including specific kidney diseases (e.g., acute interstitial nephritis, acute glomerular and vasculitic renal diseases); non-specific conditions (e.g., ischaemia, toxic injury); or extrarenal pathology (e.g., prerenal azotaemia, acute postrenal obstructive nephropathy).
* History of renal dialysis or kidney transplantation.
* History of or current malignancy requiring treatment.
* Severe cardiomyopathy or significant unstable cardiac disease within six months before screening.
* A positive test for Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) within three months before screening.
* Presence of any medical, emotional, behavioural, or psychological condition that, in the Investigator's judgement, could interfere with the subject's compliance with the requirements of the study.

Additional Exclusion Criteria for Subjects Enrolled in Stage I:

* Female
* Non-classic form of Fabry disease
* Receipt of treatment for Fabry disease within six months before screening
* Positive for anti-PRX-102 antibodies at screening

Additional Exclusion Criteria for Subjects in Stage II (i.e., non-treatment naïve males or females):

* Unwilling to discontinue current ERT treatment for Fabry disease before baseline.
* Females: Pregnant or lactating, or of childbearing potential with a fertile male partner and unwilling to use a highly reliable method of contraception from the informed consent signature until 30 days after the last infusion.

Primary outcomes:
measure: Incidence of Treatment Emergent Adverse Events (TEAEs)
timeFrame: 12 Months
measure: Incidence of Infusion Related Reactions (IRRs)
timeFrame: 12 Months
measure: Incidence of Injection site reactions (ISRs)
timeFrame: 12 Months
measure: Change in Tanner stage
timeFrame: Baseline and 12 Months
measure: Change from baseline of 12-lead ECG quantitative parameters: Mean Heart Rate
timeFrame: Baseline and 12 Months
measure: Change from baseline of 12-lead ECG quantitative parameters: PR Interval
timeFrame: Baseline and 12 Months
measure: Change from baseline of 12-lead ECG quantitative parameters: QRS Duration
timeFrame: Baseline and 12 Months
measure: Change from baseline of 12-lead ECG quantitative parameters: QT Interval
timeFrame: Baseline and 12 Months
measure: Change from baseline of 12-lead ECG quantitative parameters: QTc Interval
timeFrame: Baseline and 12 Months
measure: Change from baseline of 12-lead ECG quantitative parameters: ST Segment
timeFrame: Baseline and 12 Months
measure: Incidence of treatment-emergent Anti-Drug Antibodies (ADAs)
timeFrame: Baseline and 12 Months
measure: Incidence of premedication use at each visit and change of infusion premedications from baseline
timeFrame: Baseline and 12 Months
measure: Pharmacokinetics: Time to maximum plasma concentration (tmax)
timeFrame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
measure: Pharmacokinetic : Area under the plasma concentration-time curve from time 0 to time t (AUC0 t)
timeFrame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
measure: Pharmacokinetics: Area under the curve from time 0 to 2 weeks (AUC0-2wk)
timeFrame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
measure: Pharmacokinetics: Area under the curve from time 0 to infinity (AUC0-∞)
timeFrame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
measure: Pharmacokinetics: Terminal half-life (t1/2)
timeFrame: Baseline, week 2, week 4, week 12, week 26 and week 52]
measure: Pharmacokinetics: Area under the curve over a dosing interval (AUCτ)
timeFrame: Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
measure: Pharmacokinetics: Observed drug concentration at the end of the dosing interval (Cτ)
timeFrame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
measure: Pharmacokinetics: Clearance (Cl)
timeFrame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
measure: Pharmacokinetics: Volume of distribution (Vz)
timeFrame: Stage I - Baseline, week 2, week 4, week 12, week 26 and week 52; Stage II -Baseline, week 12, week 26 and week 52]
measure: Change in eGFR
timeFrame: Baseline and 12 Months
measure: Change in annualized eGFR slope
timeFrame: Baseline and 12 Months
measure: Change in urine albumin levels
timeFrame: Baseline and 12 Months
measure: Change in urine protein levels
timeFrame: Baseline and 12 Months
measure: Change from baseline in LVMi as assessed by echocardiogram
timeFrame: Baseline and 12 Months
measure: Change from baseline in LVMi as assessed by echocardiogram
timeFrame: Baseline and 12 Months
measure: Change from baseline in LVMi as assessed by echocardiogram
timeFrame: Baseline and 12 Months
measure: Change from baseline in LVMi as assessed by echocardiogram
timeFrame: Baseline and 12 Months
measure: Change from baseline in LVMi as assessed by echocardiogram
timeFrame: Baseline and 12 Months
measure: Incidence of any cardiac arrythmias as assessed by Holter ECG
timeFrame: Baseline and 12 Months
measure: Change in plasma levels of cardiac biomarkers
timeFrame: Baseline and 12 Months
measure: Change in plasma level of Gb3 concentration (nM)
timeFrame: Baseline and 12 Months
measure: Change in plasma level of lyso-Gb3 (nM)
timeFrame: Baseline and 12 Months
measure: Change in urine level of lyso-Gb3 (nM)
timeFrame: Baseline and 12 Months
measure: Incidence of change from baseline in the number of different pain medications
timeFrame: Baseline and 12 Months
measure: Incidence of Fabry Clinical Events
timeFrame: 12 Months
measure: Change from baseline of Mainz Severity Score Index (MSSI) scores
timeFrame: Baseline and 12 Months
measure: Change from baseline of PedsQL-GI (or GSRS for subjects who reaches 18 yrs of age) scores
timeFrame: Baseline and 12 Months
measure: Change from baseline of FPHPQ scores
timeFrame: Baseline and 12 Months
measure: Change from baseline of PedsQL-PPQ (or BPI-SF for subjects who reaches 18 yrs of age) scores
timeFrame: Baseline and 12 Months
measure: Change from baseline of EQ-5D-Y (or EQ-5D-5L for subjects who reaches 18 yrs of age) scores
timeFrame: Baseline and 12 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Phoenix Children's
state: Arizona
city: Atlanta
country: United States
facility: Emory Genetics Clinical Trials Center
state: Georgia
city: Iowa City
country: United States
facility: University of Iowa
state: Iowa
city: Grand Rapids
country: United States
facility: Vivo Infusion
state: Michigan
city: Cincinnati
country: United States
facility: Cincinnati Children's Hospital Medical Center
state: Ohio
city: Salt Lake City
country: United States
facility: University of Utah
state: Utah
city: Salzburg
country: Austria
facility: UK für Kinder- und Jugendheilkunde der PMU Salzburg
city: Bordeaux
country: France
facility: Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin
city: Montpellier
country: France
facility: Hopital Arnaud de Villeneuve
city: Bergen
country: Norway
facility: Haukeland Universitetssjukehus
city: Santiago De Compostela
country: Spain
facility: Hospital Clinico Universitario De Santiago De Compostela
city: London
country: United Kingdom
facility: Great Ormond Street Hospital for Children NHS Foundation Trust
Study officials:
References: